Sensus Healthcare is pleased to announce the acceptance and publication of the most comprehensive study to date on treating Non Melanoma Skin Cancer (NMSC) with superficial radiotherapy (SRT) in the Journal of the American Academy of Dermatology (JAAD). The comprehensive study, which examined 1,715 NMSC lesions in 1,149 patients, dubbed “Superficial x-ray in the treatment of basal and squamous cell carcinomas”, was authored by Dr. Armand Cognetta and his colleagues. The study finds that SRT is a viable and effective modality in the physician’s toolbox to successfully treat NMSC patients with high cure rates and is complimentary to surgery and other treatment methods.
“The acceptance and publication of this study by the AAD society is very important and timely, considering the contemporary clinical and economic landscape, where there is an ongoing endeavor to employ sound and cost-effective methods to treat patients non-invasively, which will essentially lower the burden on the healthcare system and the economy in general, while maximizing clinical outcomes, cure rates, and overall patient quality of life. The SRT-100™ is in the sweet spot of addressing the challenges our society is coping with nowadays, while offering the patients and physicians excellent results. We are proud to be on the forefront of providing a treatment solution that is truly beneficial to everyone involved in this equation – the patients, physicians, and the healthcare system.” stated Joe Sardano, President/CEO, Sensus Healthcare.
About Sensus Healthcare:
Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100™ systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings. SRT-100™ is an ideal treatment modality for non-melanoma skin cancers, thanks to its SharpBeam™ characteristics, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100™ is FDA, CE, and SFDA cleared and is manufactured in the United States of America under the stringent ISO-13485 and GMP quality standards.
561-922-5808 Ext. 100